CN115869221B - Liposome containing truffle extract and application thereof - Google Patents
Liposome containing truffle extract and application thereof Download PDFInfo
- Publication number
- CN115869221B CN115869221B CN202211522718.8A CN202211522718A CN115869221B CN 115869221 B CN115869221 B CN 115869221B CN 202211522718 A CN202211522718 A CN 202211522718A CN 115869221 B CN115869221 B CN 115869221B
- Authority
- CN
- China
- Prior art keywords
- liposome
- parts
- truffle extract
- truffle
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002502 liposome Substances 0.000 title claims abstract description 117
- 239000000284 extract Substances 0.000 title claims abstract description 99
- 241000609666 Tuber aestivum Species 0.000 title claims abstract description 66
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 39
- 239000003381 stabilizer Substances 0.000 claims abstract description 32
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 14
- 239000003755 preservative agent Substances 0.000 claims abstract description 12
- 230000002335 preservative effect Effects 0.000 claims abstract description 12
- 241000972296 Choiromyces meandriformis Species 0.000 claims description 36
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 25
- 238000003756 stirring Methods 0.000 claims description 24
- 239000002537 cosmetic Substances 0.000 claims description 14
- 235000011187 glycerol Nutrition 0.000 claims description 14
- 238000010438 heat treatment Methods 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 13
- 238000005303 weighing Methods 0.000 claims description 13
- 229920000058 polyacrylate Polymers 0.000 claims description 11
- -1 stearyloxy Chemical group 0.000 claims description 10
- 229940104261 taurate Drugs 0.000 claims description 10
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 9
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 9
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 9
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 9
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 9
- 238000007599 discharging Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 241000186427 Cutibacterium acnes Species 0.000 claims description 7
- 229940055019 propionibacterium acne Drugs 0.000 claims description 7
- HSFQBFMEWSTNOW-UHFFFAOYSA-N sodium;carbanide Chemical group [CH3-].[Na+] HSFQBFMEWSTNOW-UHFFFAOYSA-N 0.000 claims description 7
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 7
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 6
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000004090 dissolution Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- YPUZOECTETYPRF-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrimidine-2-carboxylic acid Chemical compound OC(=O)C1NCC=CN1 YPUZOECTETYPRF-UHFFFAOYSA-N 0.000 claims description 3
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 3
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 claims description 3
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 3
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 3
- 108010087806 Carnosine Proteins 0.000 claims description 3
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 3
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims description 3
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 3
- 229960000458 allantoin Drugs 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 229960003237 betaine Drugs 0.000 claims description 3
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 3
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims description 3
- 229940044199 carnosine Drugs 0.000 claims description 3
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims description 3
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 3
- 229940100554 isononyl isononanoate Drugs 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 3
- 229940101267 panthenol Drugs 0.000 claims description 3
- 235000020957 pantothenol Nutrition 0.000 claims description 3
- 239000011619 pantothenol Substances 0.000 claims description 3
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims description 3
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 3
- 229940032094 squalane Drugs 0.000 claims description 3
- 239000000230 xanthan gum Substances 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- NKEQOUMMGPBKMM-UHFFFAOYSA-N 2-hydroxy-2-[2-(2-hydroxy-3-octadecanoyloxypropoxy)-2-oxoethyl]butanedioic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CC(O)(C(O)=O)CC(O)=O NKEQOUMMGPBKMM-UHFFFAOYSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 230000001815 facial effect Effects 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims 1
- 229950006159 etersalate Drugs 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 abstract description 4
- 230000009471 action Effects 0.000 abstract description 2
- 230000002209 hydrophobic effect Effects 0.000 abstract description 2
- 125000001165 hydrophobic group Chemical group 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000012071 phase Substances 0.000 description 37
- 230000000052 comparative effect Effects 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 24
- 210000003491 skin Anatomy 0.000 description 23
- 239000000686 essence Substances 0.000 description 20
- 238000012360 testing method Methods 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- ZGSCRDSBTNQPMS-UJURSFKZSA-N 3-O-Ethylascorbic acid Chemical group CCOC1=C(O)C(=O)O[C@@H]1[C@@H](O)CO ZGSCRDSBTNQPMS-UJURSFKZSA-N 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- 102000012422 Collagen Type I Human genes 0.000 description 11
- 108010022452 Collagen Type I Proteins 0.000 description 11
- 102000016942 Elastin Human genes 0.000 description 9
- 108010014258 Elastin Proteins 0.000 description 9
- 229920002549 elastin Polymers 0.000 description 9
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 8
- 229960005323 phenoxyethanol Drugs 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000001514 detection method Methods 0.000 description 7
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 230000001804 emulsifying effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 3
- 229910052785 arsenic Inorganic materials 0.000 description 3
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 3
- 229910052793 cadmium Inorganic materials 0.000 description 3
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 229910001385 heavy metal Inorganic materials 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 3
- 229910052753 mercury Inorganic materials 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000001153 anti-wrinkle effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 231100000065 noncytotoxic Toxicity 0.000 description 2
- 230000002020 noncytotoxic effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000011076 safety test Methods 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 230000037394 skin elasticity Effects 0.000 description 2
- UKSFMDODPANKJI-UHFFFAOYSA-M sodium;2-[methyl(octadecanoyl)amino]ethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)N(C)CCS([O-])(=O)=O UKSFMDODPANKJI-UHFFFAOYSA-M 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- LRPFVGWWAKSVOY-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O LRPFVGWWAKSVOY-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101000851054 Homo sapiens Elastin Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 206010040830 Skin discomfort Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 102000054289 human ELN Human genes 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000001724 microfibril Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- ZZWFSUTZFZIQNU-BOXHHOBZSA-M potassium (4S)-4-amino-5-octadecoxy-5-oxopentanoate Chemical compound N[C@@H](CCC(=O)[O-])C(=O)OCCCCCCCCCCCCCCCCCC.[K+] ZZWFSUTZFZIQNU-BOXHHOBZSA-M 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- LWBVAHQZGAKXPU-BOXHHOBZSA-M sodium;(4s)-4-amino-5-octadecoxy-5-oxopentanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOC(=O)[C@@H](N)CCC([O-])=O LWBVAHQZGAKXPU-BOXHHOBZSA-M 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 150000003700 vitamin C derivatives Chemical group 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a liposome containing a truffle extract and application thereof. The liposome containing the truffle extract comprises the following components in parts by weight: 20-70 parts of truffle extract, 0.1-10 parts of phospholipid, 0.001-1 part of vesicle stabilizer, 0.001-3 parts of liposome stabilizer, 20-70 parts of glycerol and 0.1-2 parts of preservative. The lipid provided by the invention can enable the truffle extract to be released slowly, prolong the action time of the truffle extract and improve the bioavailability of the truffle extract. Meanwhile, the vesicle stabilizer and the liposome stabilizer are used, the hydrophobic groups of the hydrophobic modified polymer are adsorbed on the liposome under proper conditions to form an interconnection network of the liposome, so that the stability of the liposome is improved, the leakage of drug-loaded is avoided, and the application of the truffle is expanded.
Description
Technical Field
The invention belongs to the technical field of cosmetics, and particularly relates to a liposome containing truffle extract and application thereof.
Background
Truffle is a fungus growing under the ground surface and depends on other organisms to complete the life cycle of the truffle, and is mainly produced in peticos production areas in italy and france, yunnan, sichuan and other places in China. White truffle in the alba production area of italy can produce strong and attractive fragrance, and is considered to be truffle with the best quality. Researches prove that the white truffle extract can obviously improve the content of the skin type I collagen and inhibit melanin. With the intensive research of the white truffle extract in skin health, the rare cosmetic raw material is attracting great interest to cosmetic enterprises. According to incomplete statistics, the accumulated record number of the domestic cosmetics containing the truffle extract is expanded from 1604 parts in 2019 to 4011 parts in 2021 by the 31 th 12 th year of 2021, and the annual average increase rate is 58.13%. However, the white truffle extract is a water-soluble component, the hydrophobic property of the skin cuticle leads to relatively poor permeation of hydrophilic substances, on one hand, the effect of the white truffle is not obvious, and on the other hand, the skin surface skin care product has excessive nutrient components, so that skin oxidation is caused.
Disclosure of Invention
The technical problem to be solved by the invention is to improve the slow release performance of the truffle extract and prolong the action time of the truffle extract, so that the liposome containing the truffle extract is provided, the liposome is modified by using a surfactant, and meanwhile, the liposome can be bridged by inserting a hydrophobic group of a liposome stabilizer into a liposome membrane to form a liposome-polymer interconnection network, so that the stability of the truffle liposome is effectively improved, the problems of poor storability and easy spontaneous aggregation of the truffle extract liposome are further facilitated.
In order to achieve the above purpose, the present invention provides the following technical solutions:
In a first aspect, the present invention provides a liposome comprising a truffle extract, said liposome entrapping the truffle extract.
The membrane material of the liposome comprises phospholipid and liposome vesicle stabilizer.
The phospholipid comprises any one or two of hydrogenated lecithin and lecithin; the liposome vesicle stabilizer comprises any one or more of sodium methyl stearyl taurate, sodium stearyl glutamate and potassium stearyl glutamate.
The liposome also comprises a liposome stabilizer, wherein the stabilizer comprises any one or more of hydroxypropyl methyl cellulose stearyl oxyether, cetyl hydroxyethyl cellulose, acrylic acid (esters) and C10-30 alkanol acrylate cross-linked polymer.
The liposome comprises the following components in parts by weight: 10-80 parts of truffle extract, 0.05-12 parts of phospholipid, 0.0005-2 parts of vesicle stabilizer, 0.001-5 parts of liposome stabilizer, 20-90 parts of glycerin, 0.05-3 parts of preservative, or 20-70 parts of truffle extract, 0.1-10 parts of phospholipid, 0.001-1 part of vesicle stabilizer, 0.001-3 parts of liposome stabilizer, 20-70 parts of glycerin and 0.1-2 parts of preservative.
The preparation method of the liposome containing the truffle extract is characterized by comprising the following operation steps:
s1: weighing phospholipid, glycerol, vesicle stabilizer, liposome stabilizer and polyacrylate crosslinked polymer-6, mixing, heating to stirring and dissolving to obtain phase A;
S2: weighing the white truffle extract and the preservative, mixing, heating to 65-85 ℃ and stirring for dissolution to obtain a phase B;
s3: homogenizing the phase A, adding the phase B, homogenizing, stirring, and discharging to obtain liposome containing the truffle extract.
Further, the preparation method of the liposome containing the truffle extract is characterized by comprising the following operation steps:
s1: weighing phospholipid, glycerol, vesicle stabilizer, liposome stabilizer and polyacrylate crosslinked polymer-6, mixing, heating to 65-85deg.C, stirring and dissolving for 0.5-2 hr to obtain phase A;
S2: weighing the white truffle extract and the preservative, mixing, heating to 65-85 ℃, stirring and dissolving for 0.5-2h to obtain a phase B;
S3: homogenizing the phase A at 3000rpm, adding phase B, and homogenizing at 5000rpm for 4min. Stirring and cooling to room temperature, and discharging to obtain liposome containing the truffle extract.
In a second aspect, the present invention provides a cosmetic comprising a liposome comprising an extract of truffle according to the first aspect.
Preferably, the liposome containing the truffle extract accounts for 0.1-30% of the cosmetic.
Preferably, the cosmetic includes, but is not limited to, an aqueous solution, an emulsion, a spray, a mask.
The essence contains liposome of white truffle extract added into essence in 5 wt%, and further contains water, glycerin polyether-26, ammonium polyacryl dimethyl taurate, allantoin, xanthan gum, EDTA disodium, sodium hyaluronate, isononyl isononanoate, glycerin stearate citrate, squalane, arginine, water, butanediol, 1, 2-hexanediol, p-hydroxyacetophenone, 1, 2-pentanediol, betaine, panthenol, carnosine, tetrahydropyrimidine carboxylic acid and dipotassium glycyrrhizinate.
The beneficial effects of the invention are as follows:
1. The liposome containing the white truffle extract, which is prepared by the invention, can improve the slow release performance of the white truffle extract, prolong the acting time of the white truffle extract and improve the bioavailability of the white truffle extract, thereby improving the effect of the white truffle extract on preventing and treating skin aging.
2. The liposome containing the white truffle extract, which is prepared by the invention, adopts surfactants such as sodium methyl stearoyl taurate and the like as liposome vesicle stabilizers to construct the liposome with negative charges. Compared with neutral liposome, the charged liposome can effectively prevent aggregation and agglomeration of liposome. The rapid penetration of negatively charged liposomes helps to increase penetration of the truffle extract through the skin compared to positively charged liposomes.
3. The liposome containing the white truffle extract, which is prepared by the invention, uses hydroxypropyl methyl cellulose stearyloxy ether and the like as liposome stabilizers, so that the stability of the liposome is further improved, and the defect of poor stability of the liposome in practical application is overcome.
Liposomes are micro vesicles of a biofilm-like structure consisting of phospholipid bilayer, the inner core of the vesicle is aqueous phase, capable of encapsulating hydrophilic components, and the bilayer membrane region is oil phase, capable of encapsulating lipophilic components. Liposomes can enhance the ability of the encapsulated active ingredient to enter the stratum corneum by hydration, fusion or penetration mechanisms, enhancing the effect of the active ingredient to some extent. Liposomes are now almost ideal active ingredient carrier systems, with great biological and technical advantages, and therefore, liposomes have been chosen as carriers for truffle extracts. At the same time, histological studies showed that negatively charged liposomes diffuse through the stratum corneum and hair follicle to the dermis and lower part of the hair follicle much faster than positively charged vesicles. Therefore, the truffle extract is combined with the liposome, the liposome is modified by using a surfactant, meanwhile, a polymer chain network structure is formed by adopting liposome stabilizers such as hydroxypropyl methyl cellulose stearyl oxyether, and the truffle extract liposome is introduced into the polymer chain network structure to construct the truffle extract liposome, so that the stability of the truffle extract liposome is improved. So as to improve the transdermal property of the white truffle extract, prolong the acting time of the white truffle extract and improve the bioavailability of the white truffle extract, thereby improving the prevention and treatment effect of the white truffle extract on skin aging.
Drawings
Fig. 1: comparative examples 4-7 iodate status diagrams at various time points;
fig. 2: effect of serum on HDFn cell viability.
Detailed Description
In order to more clearly illustrate the present invention, the present invention will be further described with reference to preferred embodiments. It is to be understood by persons skilled in the art that the following detailed description is illustrative and not restrictive, and that this invention is not limited to the details given herein.
The reagents used in the following examples are all available from commercial sources.
Example 1
1G of hydrogenated lecithin, 0.25g of sodium methyl stearyl taurate, 0.75g of hydroxypropyl methyl cellulose stearyl oxyether, 2g of polyacrylate crosslinked polymer-6 and 94g of glycerin are weighed and mixed, heated to 70 ℃ and stirred for dissolution for 1h, so as to obtain a phase A;
Weighing 100g of white truffle extract and 2g of phenoxyethanol, mixing, heating to 70 ℃, stirring and dissolving for 0.5h to obtain a phase B;
Homogenizing the phase A at 3000rpm, adding phase B, and homogenizing at 5000rpm for 4min. Stirring and cooling to room temperature, and discharging to obtain liposome containing the truffle extract.
Comparative example 1
A liposome containing a truffle extract, which differs from the truffle liposome of example 1 in that it does not contain hydroxypropyl methylcellulose stearyloxy ether.
1G of hydrogenated lecithin, 0.25g of sodium methyl stearyl taurate, 2g of polyacrylate crosslinked polymer-6 and 94.75g of glycerin are weighed and mixed, heated to 70 ℃ and stirred for dissolution for 1h, so as to obtain a phase A;
Weighing 100g of white truffle extract and 2g of phenoxyethanol, mixing, heating to 70 ℃, stirring and dissolving for 0.5h to obtain a phase B;
Homogenizing the phase A at 3000rpm, adding phase B, and homogenizing at 5000rpm for 4min. Stirring and cooling to room temperature, and discharging to obtain liposome containing the truffle extract.
Comparative example 2
A liposome containing a truffle extract, which is different from the truffle liposome in example 1 in that it does not contain hydrogenated lecithin.
Weighing and mixing 0.25g of sodium methyl stearyl taurate, 0.75g of hydroxypropyl methyl cellulose stearyl oxyether, 2g of polyacrylate crosslinked polymer-6 and 95g of glycerol, heating to 70 ℃, stirring and dissolving for 1h to obtain a phase A;
Weighing 100g of white truffle extract and 2g of phenoxyethanol, mixing, heating to 70 ℃, stirring and dissolving for 0.5h to obtain a phase B;
Homogenizing the phase A at 3000rpm, adding phase B, and homogenizing at 5000rpm for 4min. Stirring and cooling to room temperature, and discharging to obtain liposome containing the truffle extract.
Comparative example 3
A liposome containing a truffle extract, which is different from the truffle liposome in example 1 in that it does not contain sodium methyl stearyl taurate.
1G of hydrogenated lecithin, 0.75g of hydroxypropyl methyl cellulose stearyloxy ether, 2g of polyacrylate crosslinked polymer-6 and 94.25g of glycerin are weighed and mixed, heated to 70 ℃ and stirred for dissolution for 1h, so as to obtain a phase A;
Weighing 100g of white truffle extract and 2g of phenoxyethanol, mixing, heating to 70 ℃, stirring and dissolving for 0.5h to obtain a phase B;
Homogenizing the phase A at 3000rpm, adding phase B, and homogenizing at 5000rpm for 4min. Stirring and cooling to room temperature, and discharging to obtain liposome containing the truffle extract.
1. Performance testing
Comparative example 1 did not contain hydroxypropyl methylcellulose stearyloxy ether, comparative example 2 did not contain hydrogenated lecithin, comparative example 3 sodium methyl stearyl taurate, and the remaining starting materials were identical to example 1.
Liposomes containing the truffle extract are generally evaluated for storage stability according to GB/T29665-2013.
The results of the general storage stability tests for example 1 and comparative examples 1-3 are shown in Table 1.
TABLE 1 general storage stability test results for examples 1-3
As is clear from Table 1, the liposomes of the extract of Propionibacterium acnes prepared in example 1 and comparative examples 1-3 have excellent general storage stability.
2. Sustained release test
In order to better illustrate that the liposome containing the white truffle extract can prolong the release time of the white truffle extract, and plays a role in slow release or long-acting. White truffle extract liposomes containing vitamin C ethyl ether were prepared according to the preparation methods of example 1 and comparative examples 1-3, respectively.
Comparative example 4
A vitamin C ethyl ether-containing extract liposome of Propionibacterium acnes, which is different from the extract liposome of Propionibacterium acnes in example 1 in phase B. Phase B of comparative example 4 was 98g of a Bitruum extract, 2g of vitamin C ethyl ether and 2g of phenoxyethanol.
Comparative example 5
A vitamin C ethyl ether-containing extract liposome of Propionibacterium acnes, which is different from that of comparative example 1 in phase B. Phase B of comparative example 5 was 98g of a white truffle extract, 2g of vitamin C ethyl ether and 2g of phenoxyethanol.
Comparative example 6
A vitamin C ethyl ether-containing extract liposome of Propionibacterium acnes, which is different from that of comparative example 2 in phase B. Phase B of comparative example 6 was 98g of a white truffle extract, 2g of vitamin C ethyl ether and 2g of phenoxyethanol.
Comparative example 7
A vitamin C ethyl ether-containing extract liposome of Propionibacterium acnes, which is different from that of comparative example 3 in phase B. Phase B of comparative example 7 was 98g of a white truffle extract, 2g of vitamin C ethyl ether and 2g of phenoxyethanol.
The method for testing the liposome slow release property of the truffle extract comprises the following steps: and respectively taking 4 split charging bottles, respectively filling 10g of comparative examples 4-7 into each bottle, simultaneously taking 4g of iodophor solution, respectively observing the fading condition of the iodophor solution in the split charging bottles along with the time change. The test results are shown in FIG. 1 and Table 2.
Vitamin C ethyl ether is a vitamin C derivative, and has strong reducibility, and oxidation-reduction reaction occurs when the vitamin C ethyl ether encounters an iodophor solution, so that the iodophor is discolored. According to the preparation method of the white truffle liposome of the example 1 and the comparative examples 1-3, white truffle extract liposome containing vitamin C ethyl ether is prepared, namely the comparative examples 4-7. The property that vitamin C ethyl ether can fade iodophor is utilized to examine the slow release effect of the truffle extract liposome. As can be seen from FIG. 1, comparative examples 5 and 7 have completely discolored after shaking up with iodine, indicating that the stability of the liposome of the extract of Prososiphon aristatus is poor and the active ingredient easily leaks after the lack of hydroxymethyl cellulose stearyloxy ether (liposome stabilizer) and sodium methyl stearoyl taurate (vesicle stabilizer). The white truffle extract liposome containing vitamin C ethyl ether prepared in comparative example 4 cannot completely fade after 30min, which shows that the white truffle extract liposome prepared in the invention has good slow release effect on the release of white truffle extract.
TABLE 2
Example 2
To better illustrate the applicability of the present invention, the liposome containing the truffle extract prepared in example 1 of the present invention was added to the essence at an addition level of 5%, and stability and safety tests were performed on the essence.
The preparation method of the essence comprises the following steps:
100g of water, 20g of glycerol polyether-26, 5g of ammonium polyacryl dimethyl taurate, 1g of allantoin, 1g of xanthan gum, 0.5g of EDTA disodium and 0.2g of sodium hyaluronate are put into a water phase pot, stirred, heated and dissolved completely, and pumped into an emulsifying pot;
adding 5g isononyl isononanoate, 5g glyceryl stearate citrate and 10g squalane into an oil phase pot, stirring, heating to dissolve completely, pumping into an emulsifying pot, and homogenizing;
adding 0.5g of arginine and 100g of water into an emulsifying pot, uniformly stirring and preserving heat;
When the temperature of the emulsifying pot is reduced to 55 ℃, adding 30g of butanediol, 6g of 1, 2-hexanediol, 6g of p-hydroxyacetophenone and 5g of 1, 2-pentanediol, and uniformly stirring;
When the temperature of the emulsifying pot is reduced below 45 ℃, 645.2g of water, 5g of betaine, 2g of panthenol, 1.05g of carnosine, 1.05g of tetrahydropyrimidine carboxylic acid, 0.5g of dipotassium glycyrrhizinate and 50g of liposome containing the truffle extract are added, uniformly stirred, and discharged to obtain the essence containing the truffle extract liposome.
Preservative efficacy testing, using international standard ISO11930:2012 (cosmetic-microbiology-cosmetic product antimicrobial protection assessment) method; the safety test adopts corresponding technical means according to the requirements of cosmetic safety technical Specification (2015 edition) to detect the safety of heavy metals (lead, mercury, arsenic and cadmium), risk substances (diethylene glycol and dioxane) and microorganisms in essence cream.
The results of the serum preservative efficacy test are shown in table 3, which shows passing the a standard in table b.1 of ISO11930-2012 appendix B.
TABLE 3 test results of preservative efficacy
The detection results of the safety of heavy metals (lead, mercury, arsenic and cadmium), risk substances (diethylene glycol and dioxane) and microorganisms in the essence are shown in tables 4 and 5. Lead, mercury, arsenic and cadmium are not detected, and the microbial index meets the standard.
Table 4 results of detection of heavy metals and risk substances in essence
TABLE 5 results of essence microorganism detection
Example 3: in vitro anti-aging effect detection
Cytotoxicity test. Human skin fibroblasts in the logarithmic growth phase (HDFn, pcs-201-010, available from ATCC American type culture institute) were collected and inoculated into 96-well plates at a cell density of 8X 10 3 cells/well, with 100. Mu.L of the culture broth per well. After 24h of incubation to form monolayer cells, the culture was continued for 48h with the addition of 5,2.5,1.25,0.63,0.31,0.16 and 0.08% strength gradient of serum, respectively. The relative activity of the cells was determined according to the CCK-8 kit assay, and the cells were treated with medium without the test substance as a negative control. The relative activity of the cells was calculated. When the relative cell activity is not less than 80%, the test substance is considered to be non-cytotoxic at this concentration.
Type I collagen synthesis capability assay. HDFn cells in log phase were collected and seeded at a cell density of 5.6X10. 10 4 cells/well in 24 well plates. After 24h incubation in incubator (37 ℃,5% co 2), medium containing essence (0.31,0.62 and 1.25%) was added with untreated cells as negative control. After the addition, the culture was continued in an incubator (37 ℃,5% CO 2) for 48 hours, and the culture broth was collected. The detection of the type I collagen content in the culture solution is carried out by adopting a human type I collagen ELISA kit.
Elastin synthesis ability test. HDFn cells in log phase were collected and seeded at a cell density of 5.6X10. 10 4 cells/well in 24 well plates. After 24h incubation in incubator (37 ℃,5% co 2), medium containing essence (0.31,0.62 and 1.25%) was added with untreated cells as negative control. After the addition, the culture was continued in an incubator (37 ℃,5% CO 2) for 48 hours, and the culture broth was collected. The detection of the elastin content in the culture solution is carried out by using a human elastin ELISA kit.
As a result. The cytotoxicity test results of the essences with different concentrations on HDFn are shown in figure 2. Compared with the negative control group, less than 5% of essence has no obvious cytotoxicity (p > 0.05) on HDFn cells. Indicating that essence with concentration below 5% is non-cytotoxic.
Collagen is the most abundant protein in dermis, so that the skin maintains certain strength and elasticity. Type I collagen accounts for 80% of total collagen, and is the main component of dermis. When skin ages, the proportion of type I collagen with the highest content in collagen is gradually reduced, collagen fiber is crosslinked abnormally, and skin elasticity is reduced, so that wrinkles are generated. Therefore, the anti-wrinkle efficacy of the serum was evaluated by testing the effect of the serum on the amount of HDFn cell type I collagen synthesis, and the results are shown in table 6. As can be seen from table 6, the serum significantly increased the amount of collagen type I synthesis by 10.02% and 13.18 (p < 0.01), respectively, after HDFn cells were added at concentrations of 0.62% and 1.25% compared to the negative control group. The essence has the capability of promoting HDFn cell type I collagen synthesis, and achieves the anti-wrinkle effect by improving HDFn cell type I collagen synthesis amount.
TABLE 6 analysis of results of type I collagen synthesis ability test
Elastin is an important extracellular matrix protein that can combine with microfibrils to form elastic fibers, where it interlaces with collagen to form a dense lamellar structure that imparts elasticity and toughness to the skin. Degradation of elastin can result in reduced skin elasticity and thus wrinkles. Therefore, the tightening efficacy of the serum was evaluated by testing the effect of the serum on the amount of HDFn cell elastin synthesis, and the results are shown in table 7. As can be seen from the results in table 7, the serum significantly increased the amount of elastin synthesis (p < 0.05) after HDFn cells were added at a concentration of 1.25% compared to the negative control. The essence has the capability of promoting HDFn cell elastin synthesis, and achieves the effect of tightening by improving HDFn cell elastin synthesis.
TABLE 7 analysis of results of elastin Synthesis Capacity test
Example 4: in vivo anti-aging effect detection
The effect of using the essence was evaluated by recruiting 35 volunteers (18 to 65 year old women without history of skin diseases and cosmetic allergies; sensitive from the facial skin, and at least 2 or more of the skin discomfort symptoms (stinging, itching, burning, redness, desquamation, etc.) to a slight degree or more). A total of 33 eligible female volunteers participated in the test based on a randomized, semi-face control design. During the test, the volunteer uses the essence on one side and the other side as a control area, and the whole face uses other daily skin care products except the essence, and the brand and the using mode of the product are kept unchanged. The essence is used for 1 time in the morning and evening respectively and continuously for 4 weeks. The double-sided cheek was subjected to skin moisture content test and skin gloss test before, after 2 weeks and after 4 weeks of use of the serum. Skin moisture content and skin gloss tests were performed using Corneometer and Glossymeter instruments, respectively, and the results are shown in table 8.
Table 8 statistics of skin moisture and gloss before and after use of the serum
The higher the skin moisture content value, the higher the skin stratum corneum moisture content. As can be seen from table 8, the skin moisture content of the serum zone was significantly improved after 2 and 4 weeks of use of the serum compared to the initial value, by 7.62 and 10.07 (p < 0.05), respectively. The skin moisture content of the serum zone was significantly better than the control zone (p < 0.05) after both 2 and 4 weeks of serum use compared to the control zone.
The larger the values of the skin Gloss parameters "Gloss value" and "Gloss with DSC" indicate the better skin Gloss. The skin Gloss parameters "Gloss value" and "Gloss with DSC" of the serum zone were significantly improved (p < 0.05) after 2 and 4 weeks of use of the test product compared to the initial values. The skin Gloss parameters "Gloss value" and "Gloss with DSC" were significantly better than the control zone (p < 0.05) after 2 and 4 weeks of use of the serum compared to the control zone.
In conclusion, it is demonstrated that the skin moisture and glossiness are remarkably improved after 2 weeks and 4 weeks of using the essence containing the truffle liposome (5%), and the moisturizing and brightening effects are shown.
Finally, it is noted that the above embodiments are only for illustrating the technical solution of the present invention and not for limiting the same, and although the applicant has described the present invention in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications and equivalents may be made thereto without departing from the spirit and scope of the technical solution of the present invention, and it is intended to be covered by the scope of the claims of the present invention.
Claims (8)
1. A liposome containing a truffle extract, characterized in that the liposome encapsulates the truffle extract;
The membrane material of the liposome comprises phospholipid and a liposome vesicle stabilizer;
The phospholipid comprises any one or two of hydrogenated lecithin and lecithin; the liposome vesicle stabilizer comprises sodium methyl stearyl taurate;
The liposome also includes a liposome stabilizer including hydroxypropyl methylcellulose stearyloxy ether and polyacrylate crosslinked polymer-6.
2. The liposome containing the truffle extract according to claim 1, which is characterized by comprising the following components in parts by weight: 10-80 parts of truffle extract, 0.05-12 parts of phospholipid, 0.0005-2 parts of liposome vesicle stabilizer, 0.001-5 parts of liposome stabilizer, 20-90 parts of glycerol, 0.05-3 parts of preservative and polyacrylate crosslinked polymer-6.
3. The liposome containing the truffle extract according to claim 2, which is characterized by comprising the following components in parts by weight: 20-70 parts of truffle extract, 0.1-10 parts of phospholipid, 0.001-1 part of liposome vesicle stabilizer, 0.001-3 parts of liposome stabilizer, 20-70 parts of glycerol, 0.1-2 parts of preservative and polyacrylate crosslinked polymer-6.
4. A method for preparing a liposome containing a truffle extract, which is applicable to the liposome containing the truffle extract according to claim 2, and is characterized by comprising the following operation steps:
S1: weighing phospholipid, glycerol, liposome vesicle stabilizer, and polyacrylate crosslinked polymer-6, mixing, heating to stirring for dissolving to obtain phase A;
S2: weighing the white truffle extract and the preservative, mixing, heating to 65-85 ℃ and stirring for dissolution to obtain a phase B;
s3: homogenizing the phase A, adding the phase B, homogenizing, stirring, and discharging to obtain liposome containing the truffle extract.
5. The method for preparing liposome containing truffle extract according to claim 4, comprising the following steps:
S1: weighing phospholipid, glycerol, liposome vesicle stabilizer, liposome stabilizer and polyacrylate crosslinked polymer-6, mixing, heating to 65-85deg.C, stirring and dissolving for 0.5-2 hr to obtain phase A;
S2: weighing the white truffle extract and the preservative, mixing, heating to 65-85 ℃, stirring and dissolving for 0.5-2h to obtain a phase B;
S3: homogenizing the phase A at a homogenizing speed of 3000rpm, adding phase B, homogenizing at a speed of 5000rpm for 4min after adding phase B, stirring, cooling to room temperature, and discharging to obtain liposome containing Propionibacterium acnes extract.
6. A cosmetic comprising the liposome containing the extract of truffle according to claim 2.
7. The cosmetic according to claim 6, wherein the liposome containing the extract of truffle is added in an amount of 0.1-30% of the cosmetic; the cosmetic is in the form of water, emulsion, spray or facial mask.
8. An essence is characterized in that: the liposome containing the truffle extract according to claim 2, wherein the liposome containing the truffle extract is added to essence liquid in an amount of 5%, and the liposome further comprises water, glycereth-26, ammonium polyacryl dimethyl taurate, allantoin, xanthan gum, disodium EDTA, sodium hyaluronate, isononyl isononanoate, glyceryl stearate citrate, squalane, arginine, butanediol, 1, 2-hexanediol, p-hydroxyacetophenone, 1, 2-pentanediol, betaine, panthenol, carnosine, tetrahydropyrimidine carboxylic acid and dipotassium glycyrrhizinate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211522718.8A CN115869221B (en) | 2022-11-30 | 2022-11-30 | Liposome containing truffle extract and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211522718.8A CN115869221B (en) | 2022-11-30 | 2022-11-30 | Liposome containing truffle extract and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115869221A CN115869221A (en) | 2023-03-31 |
| CN115869221B true CN115869221B (en) | 2024-09-13 |
Family
ID=85765066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211522718.8A Active CN115869221B (en) | 2022-11-30 | 2022-11-30 | Liposome containing truffle extract and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115869221B (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018015583A (en) * | 2016-06-15 | 2019-05-16 | Ojai Energetics Pbc | Methods and compositions for reducing oxidative stress. |
| FR3059231B1 (en) * | 2016-11-29 | 2019-09-20 | L'oreal | COMPOSITION COMPRISING A TRUFFLE EXTRACT AND A DIHYDROCHALCONE |
| CN107961191A (en) * | 2017-12-28 | 2018-04-27 | 广州蜜妆生物科技有限公司 | A kind of kahikatea dew anti-aging is compacted eye mask and preparation method thereof |
| KR102551369B1 (en) * | 2018-09-06 | 2023-07-05 | (주) 에이치엔에이파마켐 | Transparent liposome composition containing centella asiatica extract |
-
2022
- 2022-11-30 CN CN202211522718.8A patent/CN115869221B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN115869221A (en) | 2023-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4099173B2 (en) | Cosmetic or dermopharmaceutical composition comprising kombucha | |
| CN111450008A (en) | Whitening cream and preparation method thereof | |
| CN111671716A (en) | Antioxidant skin color brightening composition and application thereof in cosmetics | |
| MX2012013647A (en) | Topical pharmaceutical or cosmetic composition useful for the treatment of diseases or conditions that transcur through a deficit of maturation of the cornified envelope. | |
| KR101435874B1 (en) | Cosmetic composition comprising extract Curcuma longa Linne leaf and manufacturing method thereof | |
| KR102582633B1 (en) | Cosmetic composition for skin regeneration and wrinkle improvement containing epidermal growth factor liposomes and growth factor complex | |
| EP0949919B1 (en) | A process for stabilizing levogyre ascorbic acid (laa) and stable laa compositions | |
| CN111514058A (en) | Skin whitening and brightening agent and preparation method thereof | |
| CN115869221B (en) | Liposome containing truffle extract and application thereof | |
| EP1147765B1 (en) | New active, compositions containing it and it's use in cosmetic, dermocosmetic, dermopharmacy or pharmacy, on woven or nonwoven fabrics | |
| CN116509774B (en) | Anti-dandruff shampoo preparation containing sweet wormwood herb extract and preparation method thereof | |
| CN110339079B (en) | Composition comprising amide derivatives and use thereof in cosmetics | |
| CN115337211B (en) | Mild hyposensitization moisturizing acne-removing gel and preparation method thereof | |
| CN115737478B (en) | Application of desert algae skin care raw material in preparation of skin soothing agent | |
| CN116785202A (en) | Multiple skin care essence with suspended grease and preparation method thereof | |
| CN115813774A (en) | Water-oil double-layer refined composition with whitening effect and preparation method and application thereof | |
| CN116509766A (en) | Green tea symbiotic fermentation liquor with antioxidant, oil control and anti-wrinkle effects and preparation method and application thereof | |
| CN117257695A (en) | Fermented water-oil double-layer composition and preparation method and application thereof | |
| CA2278226C (en) | Cosmetic or dermo-phamaceutical products compatible with cutaneous ecology | |
| CN110123735A (en) | Skin care compositions with multi-faceted maintenance skin, anti-senescence function | |
| KR102334706B1 (en) | Niosome composition comprising stabilized retinal and personal care composition containing the same | |
| CN117426999B (en) | Recyclable antioxidant efficient delivery nano-composite and preparation method thereof | |
| CN115429712B (en) | Polypeptide and fullerene co-delivery nano composition, and preparation method and application thereof | |
| CN113876642B (en) | A facial cream composition containing lipid nanoparticle with moisturizing effect and its preparation method | |
| US6685965B1 (en) | Process for stabilizing levogyre ascorbic acid (laa), a stable aqueous laa composition, a process for preparing a stable topical solution, an emulsion, a vitamin product, and a method for cosmetic, pharmaceutical or nutritional treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |